deltatrials
Terminated PHASE2 INTERVENTIONAL 3-arm NCT03912818

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Phase 2 Open Label Study of Durvalumab With Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer

Sponsor: AstraZeneca

Conditions Bladder Adenocarcinoma Bladder Mixed Adenocarcinoma Bladder Squamous Cell Carcinoma Bladder Urothelial Carcinoma Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant Infiltrating Bladder Urothelial Carcinoma With Giant Cells Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation Infiltrating Bladder Urothelial Carcinoma With Trophoblastic Differentiation Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant Infiltrating Bladder Urothelial Carcinoma, Nested Variant Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant
Interventions Carboplatin Cisplatin Cystectomy Doxorubicin Durvalumab Gemcitabine Methotrexate Vinblastine
Updated 11 times since 2019 Last updated: Aug 15, 2023 Started: Apr 10, 2019 Primary completion: Aug 11, 2022 Completion: Aug 11, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Difficulty with enrollment

Other terminated trials from AstraZeneca

More terminations from AstraZeneca

Listed as NCT03912818, this PHASE2 trial focuses on Bladder Adenocarcinoma and Bladder Mixed Adenocarcinoma and remains terminated or withdrawn. Sponsored by AstraZeneca, it has been updated 11 times since 2019, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~May 2019 – ~Jun 2019 · 31 days · monthly snapshotRecruiting~Jun 2019 – ~Nov 2019 · 5 months · monthly snapshotRecruiting~Nov 2019 – ~Feb 2020 · 3 months · monthly snapshotRecruiting~Feb 2020 – ~Aug 2020 · 6 months · monthly snapshotRecruiting~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshotRecruiting~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshotRecruiting~Sep 2021 – ~May 2022 · 8 months · monthly snapshotRecruiting~May 2022 – ~Oct 2023 · 17 months · monthly snapshotActive Not Recruiting~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 23 months · monthly snapshotTerminated

Change History

11 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Oct 2023 — Jul 2024 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  4. May 2022 — Oct 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Sep 2021 — May 2022 [monthly]

    Recruiting PHASE2

▶ Show 6 earlier versions

  1. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  2. Aug 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  3. Feb 2020 — Aug 2020 [monthly]

    Recruiting PHASE2

  4. Nov 2019 — Feb 2020 [monthly]

    Recruiting PHASE2

  5. Jun 2019 — Nov 2019 [monthly]

    Recruiting PHASE2

  6. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE2

    First recorded

Apr 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
  • Stanford University
Data source: Stanford University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations